Skip navigation Scroll to top

Scroll to top

Novartis presents a more confident full-year guidance

July 17, 2013

Novartis increased its full-year guidance due to a delayed market entry of generic Diovan in the U.S. and slightly better than expected first-half year results. Europe’s biggest drugmaker now forecast a “low single-digit percentage” decline in adjusted operating profit in 2013 and a gain in revenues. Previously, Novartis had predicted profit to decrease by a “mid single-digit percentage” and stagnating sales.